Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ASTX727 consists of the combination of decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Giving nivolumab in combination with ASTX727 may shrink and stabilize cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony chłoniak z komórek B, który powrócił po leczeniu lub nie reaguje na leczenie
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (skala wydolności ≤2)
- •Wystarczająca liczba białych krwinek, neutrofili i płytek krwi
- •Prawidłowa funkcja wątroby (bilirubina i enzymy wątrobowe poniżej normy)
- •Pacjenci z DLBCL muszą mieć nieudane co najmniej pierwsze leczenie chemioterapią
- •Pacjenci z innymi typami chłoniaka muszą mieć nieudane co najmniej dwie linie leczenia
✗ Disqualifies
- •Wiek poniżej 18 lat
- •Zbyt słaby ogólny stan zdrowia do uczestniczenia w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (9)
University of Alabama at Birmingham Cancer Center
Birmingham, United States
City of Hope Comprehensive Cancer Center
Duarte, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
Yale University
New Haven, United States
University of Chicago Comprehensive Cancer Center
Chicago, United States
UC Comprehensive Cancer Center at Silver Cross
New Lenox, United States
University of Chicago Medicine-Orland Park
Orland Park, United States
NYU Langone Hospital - Long Island
Mineola, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, United States
Trial contact
Site Public Contact
Matthew Mei
PRINCIPAL_INVESTIGATOR
Site Public Contact
Joseph M. Tuscano
PRINCIPAL_INVESTIGATOR
Site Public Contact
Tarsheen Sethi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Justin P. Kline
PRINCIPAL_INVESTIGATOR
Site Public Contact
Catherine S. Diefenbach
PRINCIPAL_INVESTIGATOR
Site Public Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.